

New bioactive metabolites from the elicited marine sponge-derived bacterium *Actinokineospora spheciospongiae* sp. nov.

Ahmed Tawfike^{1,2}, Eman Zekry Attia³, Samar Yehia Desoukey³, Dina Hajjar⁴, Arwa A Makki⁴, Peter J. Schupp^{5*}, RuAngelie Edrada-Ebel¹, and Usama Ramadan Abdelmohsen^{3*}

¹ Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 27 Taylor Street, G4 0NR Glasgow, UK; ahmed.tawfike@rothamsted.ac.uk (A.T); ruangelie.edrada-ebel@strath.ac.uk (R. E)

² Department of Pharmacognosy, Faculty of Pharmacy, Helwan University, Cairo11753, Egypt

³ Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt; eman_zekry@mu.edu.eg (E.Z.A); drsamaryehia@gmail.com (S.Y.D); usama.ramadan@mu.edu.eg (U.R.A)

⁴ Department of Biochemistry, faculty of Science, Center for Science and medical research, University of Jeddah, 80203 Jeddah, Saudi Arabia; Dhajjar@uj.edu.sa (D.H); amaki@uj.edu.sa (A.A.M)

⁵ Carl-von-Ossietzky University Oldenburg, Institute for Chemistry and Biology of the marine Environment, Postfach 2503, 26111 Oldenburg, Germany; peter.Schupp@uni-oldenburg.de

* Correspondence: usama.ramadan@mu.edu.eg, Tel.: +2-86-2347759, Fax: +2-86-2369075 (URA); peter.schupp@uni-oldenburg.de, Tel.: ++49 (0) 4421- 944-100, Fax: +49 (0) 4421- 944-140 (PJS)

Fridamycin H ESI Positive 0911




Figure S1. HR-ESIMS spectrum of compound 1 (Fridamycin H)




Figure S2. $^1\text{H-NMR}$ spectrum of compound 1 (Fridamycin H) in $\text{DMSO-}d_6$ (600 MHz)




Figure S3. ^{13}C -NMR spectrum of compound 1 (Fridamycin H) in $\text{DMSO-}d_6$ (150 MHz)





Figure S4: ^1H - ^1H COSY spectrum of compound 1 (Fridamycin H) in $\text{DMSO-}d_6$





Figure S5: HSQC spectrum of compound 1 (Fridamycin H) in DMSO-*d*₆





Figure S6: HMBC spectrum of compound 1 (Fridamycin H) in DMSO-*d*₆




Figure S7. HR-ESIMS spectrum of compound 2 (Fridamycin I)




Figure S8. ¹H-NMR spectrum of compound 2 (Fridamycin I) in DMSO-*d*₆ (600 MHz)




Figure S9. ^{13}C -NMR spectrum of compound 2 (Fridamycin I) in $\text{DMSO-}d_6$ (150 MHz)





Figure S10: ^1H - ^1H COSY spectrum of compound 2 (Fridamycin I) in DMSO- d_6





Figure S11: HSQC spectrum of compound 2 (Fridamycin I) in DMSO-*d*₆





Figure S12: HMBC spectrum of compound 2 (Fridamycin I) in DMSO-*d*₆




Figure S13: ¹H-NMR spectrum of Actinosporin C in MeOD (600 MHz)




Figure S14: ^{13}C -NMR spectrum of Actinosporin C in MeOD (150 MHz)





Figure S15: HBMBC spectrum of Actinosporin C in MeOD




Figure S16: $^1\text{H-NMR}$ spectrum of Actinosporin D in MeOD (600 MHz)




Figure S17: ^{13}C -NMR spectrum of Actinosporin D in MeOD (150 MHz)





Figure S18: HBMBC spectrum of Actinosporin D in MeOD




Figure S19: ¹H-NMR spectrum of Actinosporin G in MeOD (600 MHz)




Figure S20: ^{13}C -NMR spectrum of Actinosporin G in MeOD (150 MHz)





Figure S21: HMBC spectrum of Actinosporin G in MeOD